Skip to content

Dietary Phytoestrogens, Complementary and Alternative Medicine, and Lifestyle in Predicting Survival of Women With Breast Cancer

The Role of Diet, Complementary Treatment and Lifestyle in Breast Cancer Survival

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00691509
Enrollment
2300
Registered
2008-06-05
Start date
2005-01-31
Completion date
Unknown
Last updated
2013-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

breast cancer

Brief summary

RATIONALE: Eating a diet rich in phytoestrogens may slow the growth of breast cancer cells and prevent further tumor progression. Learning about the lifestyles of women with breast cancer, their intake of phytoestrogens derived from food and supplements, and their use of complementary or alternative medicine (CAM) practices may help doctors learn more about breast cancer. PURPOSE: This clinical trial is studying the effect of dietary and supplemental phytoestrogens and CAM therapies in preventing progression and improving survival of women with breast cancer.

Detailed description

OBJECTIVES: * To determine if phytoestrogen intake affects breast cancer progression and survival in women with breast cancer. * To consider the influence of other phytochemicals on breast cancer progression in these patients, using samples of patient blood and urine and patient-derived data. * To develop a database of food, dietary supplements, and phytoestrogens based on data derived from these patients. * To consider influences of diet and dietary supplements on quality of life of these patients. * To measure 17 phytoestrogens in blood and urine samples from these patients. OUTLINE: This is a multicenter study. Patients undergo blood and urine sample collection once a year for 5 years during routine clinical follow-up after breast cancer diagnosis and treatment. Blood samples are frozen for future analysis of body hormones, tumor markers, and immune reactions, as well as vitamins and plant chemicals reflecting patient diet and supplements. Blood samples are also analyzed for genetic studies of cancer risk factors and polymorphisms. Urine samples are analyzed for the presence of phytoestrogens and their metabolites by immunoassays, high performance liquid chromatography (HPLC), and mass spectrometry. Some samples are analyzed for estrogenic potency by the estrogen receptor-mediated chemical activated luciferase gene expression test to assess total plasma levels of estrogen-mimics not previously detected by the other tests. Phytochemicals are also assessed. Patients also complete a series of questionnaires once each year for 5 years and an EPIC 7-day Food Diary in years 2 and 4 to assess the role of diet and lifestyle in breast cancer survival. The questionnaires include the EORTC Quality of Life-30 to assess lifestyle; the General Health Questionnaire 12 to assess general health and levels of anxiety; and up to two Food Frequency questionnaires to assess habitual dietary intake of phytoestrogens. Patients are also asked about their use of dietary supplements and complementary and alternative medicine.

Interventions

GENETICgene expression analysis
GENETICpolymorphism analysis
OTHERhigh performance liquid chromatography
OTHERlaboratory biomarker analysis
OTHERmass spectrometry
OTHERquestionnaire administration

Sponsors

University College London Hospitals
Lead SponsorOTHER

Eligibility

Sex/Gender
FEMALE
Age
No minimum to 75 Years
Healthy volunteers
No

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed invasive primary breast cancer * Grade I to III disease * No bilateral disease * Completed active treatment for primary breast cancer within 9 months to 15 months after diagnosis * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Menopausal status not specified * No prior cancer except basal cell carcinoma * No other concurrent primary cancer * No cognitive impairment * No psychological problems (e.g., severe endogenous depression) * Able to understand English well PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Design outcomes

Primary

MeasureTime frame
Relapse-free survival

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026